VoteMate Launches to Help Every American Vote with Confidence

VoteMate Launches to Help Every American Vote with Confidence The first nonprofit, nonpartisan AI app built for voters, by voters–helping every voter make confident, informed choices GlobeNewswire October 16, 2025 LOS ANGELES, Oct. 16, 2025 (GLOBE NEWSWIRE) — Voting should be simple. Yet for millions of Americans, understanding a long, complex ballot can feel overwhelming. […]

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases

Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases GlobeNewswire October 16, 2025 DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to

Mining commences at Kiniero as project tracks towards first gold in Q4 CY2025

Mining commences at Kiniero as project tracks towards first gold in Q4 CY2025 GlobeNewswire October 16, 2025 Highlights: Robex's Kiniero Gold Project, Guinea, remains on track and budget for first gold pour in Q4 CY25. The Kiniero project remains LTI free (lost time injury) with 4,857,704 hours complete to 30 September 2025. Mine development activities

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire October 16, 2025 WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to

Scripps National Spelling Bee, Scripps Howard Fund launch campaign to empower next generation of spellers

Scripps National Spelling Bee, Scripps Howard Fund launch campaign to empower next generation of spellers Now through Dec. 31, donations to Beelieve will be matched to fund Bee participation for schools in under-resourced communities GlobeNewswire October 16, 2025 CINCINNATI, Oct. 16, 2025 (GLOBE NEWSWIRE) — The Scripps Howard Fund and the Scripps National Spelling Bee

Plug Power CEO Andy Marsh to Join Senator Bill Cassidy at Louisiana Energy Security Summit

Plug Power CEO Andy Marsh to Join Senator Bill Cassidy at Louisiana Energy Security Summit GlobeNewswire October 16, 2025 SLINGERLANDS, N.Y., Oct. 16, 2025 (GLOBE NEWSWIRE) — Plug Power (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, announces that CEO Andy Marsh will join U.S. Senator Bill Cassidy (R-LA) and

Caliber Continues to Increase Chainlink (LINK) Token Exposure with an Additional $2.0 Million Acquisition

Caliber Continues to Increase Chainlink (LINK) Token Exposure with an Additional $2.0 Million Acquisition Caliber's Holdings Increased to 562,535 LINK Tokens GlobeNewswire October 16, 2025 SCOTTSDALE, Ariz., Oct. 16, 2025 (GLOBE NEWSWIRE) — Caliber (NASDAQ: CWD), a leading diversified real estate and digital asset management platform, today announced the completion of a strategic $2.0 million

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor GlobeNewswire October 16, 2025 Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the

BPGbio Presents Phase 2 Glioblastoma Data on BPM31510 at ESMO 2025

BPGbio Presents Phase 2 Glioblastoma Data on BPM31510 at ESMO 2025 GlobeNewswire October 16, 2025 BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510 Data further validate the MOA of BPM31510's direct targeting of mitochondrial redox machinery to re-potentiate apoptosis in highly aggressive tumor type BOSTON, Oct.

Ligand to Host Investor Day on December 9, 2025

Ligand to Host Investor Day on December 9, 2025 GlobeNewswire October 16, 2025 JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9, 2025 from 10:30 a.m. to 12:00 p.m. Eastern Time at The

Scroll to Top